📰 Virtual Biotech News
Virtual Biotech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Virtual Biotech. Real-time updates on events, politics, business and more.
April 27, 2024
Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson’s. NLRP3 is a protein that plays a role in regulating a number of inflammatory processes that are believed to contribute to the damage to brain cells that underlies Parkinson’s.
July 7, 2023
The findings are being revealed at the World Parkinson’s Congress in Barcelona, Spain.
July 7, 2023
The findings are being revealed at the World Parkinson’s Congress in Barcelona, Spain.
July 7, 2023
The findings are being revealed at the World Parkinson’s Congress in Barcelona, Spain.
July 6, 2023
The findings are being revealed at the World Parkinson’s Congress in Barcelona, Spain.
July 6, 2023
The findings are being revealed at the World Parkinson’s Congress in Barcelona, Spain.
March 28, 2023
/PRNewswire/ -- The Parkinsons Foundation brings Parkinsons disease (PD) to the forefront with the launch of a new awareness campaign, #Take6forPD. April is...
November 9, 2022
£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling studiesDeveloping a pipeline of
November 9, 2022
Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its investment into neuroscience company NRG Therapeutics as part of its £16m (AUD$29m) series A financing. Brandon Capital participated alongside Omega Funds, which led the round, as well as NRG’s founding investor ...
November 9, 2022
£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling...